NPS Reports Positive Phase III Extension Data For Gattex
This article was originally published in The Pink Sheet Daily
Executive Summary
Short-bowel syndrome candidate demonstrates long-term safety and tolerability, meets efficacy endpoints.
You may also be interested in...
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.